Haematologica (Aug 2023)

Regulatory T-cell dysfunctions are associated with increase in tumor necrosis factor α in autoimmune hemolytic anemia and participate in Th17 polarization

  • Marion Ciudad,
  • Sethi Ouandji,
  • Baptiste Lamarthée,
  • Claudie Cladière,
  • Thibault Ghesquière,
  • Martin Nivet,
  • Marine Thébault,
  • Romain Boidot,
  • Agnès Soudry-Faure,
  • Sandy Chevrier,
  • Corentin Richard,
  • Thibault Maillet,
  • François Maurier,
  • Hélène Greigert,
  • Coraline Genet,
  • André Ramon,
  • Malika Trad,
  • Valérie Predan,
  • Philippe Saas,
  • Maxime Samson,
  • Bernard Bonnotte,
  • Sylvain Audia

DOI
https://doi.org/10.3324/haematol.2023.282859
Journal volume & issue
Vol. 109, no. 2

Abstract

Read online

Warm autoimmune hemolytic anemia (wAIHA) is a rare acquired autoimmune disease mediated by antibodies targeting red blood cells. The involvement of CD4 T-helper cells has been scarcely explored, with most findings extrapolated from animal models. Here, we performed quantification of both effector T lymphocytes (Teff) and regulatory T cells (Treg), associated with functional and transcriptomic analyses of Treg in human wAIHA. We observed a shift of Teff toward a Th17 polarization concordant with an increase in serum interleukin-17 concentration that correlates with red blood cell destruction parameters, namely lactate dehydrogenase and bilirubin levels. A decrease in circulating Treg, notably effector Treg, associated with a functional deficiency, as represented by their decrease capability to inhibit Teff proliferation, were also observed. Treg deficiency was associated with a reduced expression of Foxp3, the master transcription factor known to maintain the Treg phenotype stability and suppressive functions. Transcriptomic profiling of Treg revealed activation of the tumor necrosis facto (TNF)-α pathway, which was linked to increased serum TNF-α concentrations that were twice as high as in controls. Treg transcriptomic profiling also suggested that post-translational mechanisms possibly accounted for Foxp3 downregulation and Treg dysfunctions. Since TNF-α participates in the rupture of immune tolerance during wAIHA, its inhibition could be of interest. To this end, the effects of fostamatinib, a SYK inhibitor, were investigated in vitro, and we showed that besides the inhibition of erythrocyte phagocytosis by monocytes, fostamatinib is also able to dampen TNF-α production, thus appearing as a promising multitargeting therapy in wAIHA (clinicaltrials gov. Identifier: NCT02158195).